Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients

AIDS

Volumn 12, Issue 11, 1998, Pages

  Casado, Jose L ^a   Perez Elías, Maria J ^a   Antela, Antonio ^a   Sabido, Raquel ^a   Martí Belda, Paloma ^a   Dronda, Fernando ^a   Blazquez, Jesús ^a   Quereda, Carmen ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Antiretroviral therapy; HIV; Protease inhibitors; Treatment failure; Viral load

Indexed keywords

CD4 ANTIGEN; INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ADULT; AGED; ARTICLE; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGRESSION ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0032581604     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199811000-00005     Document Type: Article

References (20)

1. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
2. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Eng J Med 1997, 337:734-739.
3. Carpenter CCJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA panel. JAMA 1996, 276:146-154.
4. Carpenter CCI, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA 1997, 277:1962-1969.
5. Mellors JW: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272:1167-1170.
6. Condra JH, Schleif WA, Blahy OM, et al.: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
7. Fätkenheuer G, Theisen A, Rockstroh J, et al.: Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997, 11:F113-F116.
8. Demeter L, Hughes M, Fischl M, et al.: Predictors of virologic and clinical responses to indinavir +ZDV+ 3TC or ZDV+3TC. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 509].
9. Raboud JM, Montaner JSG, Rae S, et al.: Predictors of duration of plasma viral load suppression. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September-October 1997 [abstract A-14].
10. Markowitz M, Saag M, Powderly WG, et al.: A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995, 333:1534-1539.
11. Cameron DW, Japour A, Mellors JW, et al.: Antiretroviral safety and durability of ritonavir-saquinavir in protease inhibitor-naive patients in year two of follow-up. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 388].
12. Beach RS, Wohlfeiler MB, Silva A: Indinavir-nevirapine combination therapy in advanced HIV-1 infection. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 428].
13. Phillips AN, Fron JJ, Bartlett JA, et al: HIV-1 RNA levels and the development of clinical disease. AIDS 1996, 10:859-865.
14. Condra JH, Holder DJ, Schleif WA, et al.: Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type I protease inhibitor. J Virol 1996, 70:8270-8276.
15. Rubio A, Gomez-Cano M, Puig T, et al.: Prevalence of resistance to nucleoside analogues in Spain (1993-97) among naive and pretreated patients (ERASE study). Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 673].
16. Sommadossi J-P, Valantin MA, Zhou XJ, et al.: Intracellular phosphorylation of stavudine (d4T) and 3TC correlates with their antiviral activity in naive and zidovudine experienced HIV-infected patients. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 362].
17. Noble S, Faulds D: Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 1996, 52:93-112.
18. Schapiro JM, Winters MA, Stewart F, et al.: The effect of high-dose saquinavir on viral load and CD4 T-cell counts in HIV-infected patients. Ann Intern Med 1996, 124:1039-1050.
19. Slater L, the NV15355 study: Activity of a new formulation of saquinavir in combination with two nucleosides in treatment naive patients. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 368].
20. Hecht FM, Colfax G, Swanson M, Chesney MA: Adherence and effectiveness of protease inhibitors in clinical practice. Fifth Conference on Retrovirus and Opportunistic Infections. Chicago, February 1998 [abstract 151].